Fidelity International’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$67.8M Buy
1,029,673
+27,413
+3% +$2.13M 0.05% 294
2026
Q2
$74.6M Buy
1,002,260
+1,002,172
+1,138,832% +$70.2M 0.05% 288
2026
Q1
$6.54K Buy
+88
New +$6.38K ﹤0.01% 1095
2019
Q3
– Sell
-289,448
Closed -$7.81M – 894
2019
Q2
$7.81M Buy
+289,448
New +$7.89M 0.01% 495

Other funds holding BBIO

Fidelity International's BBIO Position: Q3 2026 in Review

Fidelity International increased its BridgeBio Pharma (BBIO) stake by 2.7% in Q3 2026, buying an estimated $2.13M and bringing the position to 1,029,673 shares worth $67.8M. The position accounts for 0.05% of the portfolio, ranked #294.

Fidelity International first reported a position in BBIO in Q2 2019 and has held it in 4 quarters since. The position peaked at $74.6M in Q2 2026. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Fidelity International held 1,029,673 shares of BridgeBio Pharma worth $67.8M as of Q3 2026.
  • Fidelity International bought 27,413 BridgeBio Pharma shares in Q3 2026, an estimated $2.13M.
  • BridgeBio Pharma made up 0.05% of Fidelity International's portfolio in Q3 2026, its #294 holding.
  • Fidelity International first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 4 quarters since.
  • Fidelity International's BridgeBio Pharma position peaked at $74.6M in Q2 2026.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Fidelity International's 13F filing for Q3 2026, filed 10 Nov 2026.